Home > Insider Trading > Filing (0000921895-19-001056)

Filing Details

Accession Number:: 0000921895-19-001056
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-04-09 18:39:20
Reporting Period:: 2019-04-05

Accepted Time:: 2019-04-09 18:39:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1640809	22Nw Fund, Lp	1455 Nw Leary Way Suite 400 Seattle WA 98107	No	No	Yes	Yes
1694297	22Nw, Lp	1455 Nw Leary Way, Suite 400 Seattle WA 98107	No	No	Yes	Yes
1770436	R. Aron English	1455 Nw Leary Way, Suite 400 Seattle WA 98107	No	No	Yes	Yes
1770575	22Nw Fund Gp, Llc	1455 Nw Leary Way, Suite 400 Seattle WA 98107	No	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-05	50,000	$6.12	1,142,263	No	4	P	Indirect	By: 22NW Fund, LP
Common Stock	Acquisiton	2019-04-08	32,873	$5.81	1,175,136	No	4	P	Indirect	By: 22NW Fund, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By: 22NW Fund, LP
No	4	P	Indirect	By: 22NW Fund, LP

Footnotes

This Form 4 is filed jointly by 22NW Fund, LP ("22NW Fund"), 22NW, LP ("22NW"), 22NW Fund GP, LLC ("22NW GP") and Aron R. English (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by 22NW Fund. As the general partner and investment adviser to 22NW Fund, 22NW may be deemed to beneficially own the securities owned directly by 22NW Fund. As the general partner of 22NW, 22NW GP may be deemed to beneficially own the securities owned directly by 22NW Fund. Mr. English, as the Portfolio Manager of 22NW and Managing Member of 22NW GP, may be deemed to beneficially own the securities owned directly by 22NW Fund.
The reported price in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $6 to $6.45, excluding commissions. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $5.72 to $5.85, excluding commissions. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock purchased at each separate price within the range set forth in this footnote.